Huiling Xiong
Overview
Explore the profile of Huiling Xiong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang M, Luo S, Yang J, Xiong H, Lu X, Ma X, et al.
EXCLI J
. 2024 Oct;
23:1185-1207.
PMID: 39421026
Chronic atrophic gastritis (CAG) is considered as a significant risk factor for triggering gastric cancer incidence, if not effectively treated. decoction (SD) is a well-known classic formula for treating gastric...
2.
Luo S, Huang M, Lu X, Zhang M, Xiong H, Tan X, et al.
Phytomedicine
. 2024 Apr;
129():155573.
PMID: 38583348
Background: Cholestatic hepatitis is recognized as a significant contributor to the development of liver fibrosis and cirrhosis. As a well-known classic formula for the treatment of cholestatic hepatitis, Yinchenhao decoction...
3.
Li Y, Deng X, Xiong H, Hu Q, Chen Y, Zhang W, et al.
Front Pharmacol
. 2023 Nov;
14:1278014.
PMID: 37915415
In Chinese medicine, the primary considerations revolve around toxicity and effect. The clinical goal is to achieve maximize effect while minimizing toxicity. Nevertheless, both clinical and experimental research has revealed...
4.
Xiong H, Hu M, Huang H, Gong J, Wu J, Zhang H
Transl Cancer Res
. 2022 Feb;
8(6):2242-2251.
PMID: 35116977
Background: This study aimed to detect eukaryotic translation initiation factor 3B (EIF3B) expression in gastric cancer (GC) cell lines, and further explore the effect of EIF3B downregulation on GC cell...
5.
Park K, Ozguroglu M, Vansteenkiste J, Spigel D, Yang J, Ishii H, et al.
J Thorac Oncol
. 2021 Apr;
16(8):1369-1378.
PMID: 33845211
Introduction: In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report...
6.
Moehler M, Dvorkin M, Boku N, Ozguroglu M, Ryu M, Muntean A, et al.
J Clin Oncol
. 2020 Nov;
39(9):966-977.
PMID: 33197226
Purpose: The role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti-programmed death ligand-1 [PD-L1]) maintenance after first-line induction chemotherapy for GC/GEJC....
7.
Chung H, Arkenau H, Lee J, Rha S, Oh D, Wyrwicz L, et al.
J Immunother Cancer
. 2019 Feb;
7(1):30.
PMID: 30717797
Background: We evaluated the antitumor activity and safety of avelumab, a human anti-PD-L1 IgG1 antibody, as first-line switch-maintenance (1 L-mn) or second-line (2 L) treatment in patients with advanced gastric/gastroesophageal...
8.
Moehler M, Ryu M, Dvorkin M, Lee K, Coskun H, Wong R, et al.
Future Oncol
. 2018 Nov;
15(6):567-577.
PMID: 30379568
Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in early phase studies in advanced/metastatic gastric/gastroesophageal junction cancer, including as first-line maintenance therapy. Here, we describe...
9.
Vidovic S, Mangalappalli-Illathu A, Xiong H, Korber D
Food Microbiol
. 2012 Feb;
30(2):457-64.
PMID: 22365361
Escherichia coli, a commensal mesophile that primarily inhabits the gastro-intestinal tract, responds to temperature up-shifts with transient expression of stress-response proteins. The goal of this study was to identify adaptive...
10.
Chu D, Cheng P, Xiong H, Zhang J, Liu S, Hou X
Int J Colorectal Dis
. 2010 Nov;
26(5):569-74.
PMID: 21063714
Purpose: Visceral hypersensitivity is an important pathological mechanism of irritable bowel syndrome. Electroacupuncture (EA) could relieve chronic visceral hypersensitivity (CVH) in rats. However, little information is available about the mechanism....